Page
%P
-
Article
Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group
Myeloproliferative neoplasms (MPN) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized clinically by the proliferation of one or more hematopoietic lineage(s). The classical Phi...
-
Article
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reaction
Relapse after allogeneic haematopoietic stem cell transplantation (HSCT) is one of the key determinants of outcome in myelofibrosis (MF) and remains an important unmet need. In this retrospective single-centre...
-
Article
Open AccessAcute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
The epidemiology and treatment of acute promyelocytic leukaemia (APL) are changing. We have incorporated oral arsenic trioxide (oral-ATO) into induction/maintenance.
-
Chapter
Role of IDH1/IDH2 Inhibitors in AML
Mitochondrial activity is fundamental to supporting cellular metabolisms of almost all types of body cells. This carries paramount significance for the treatment of AML due to the presence of mitochondrial abn...
-
Chapter
Frontline Management of Acute Promyelocytic Leukemia
In the frontline management of acute promyelocytic leukemia (APL), prevention of early deaths and the selection of the optimal frontline induction strategies incorporating arsenic trioxide (ATO) and all-trans ...
-
Chapter
Management of Relapsed or Refractory AML
Standard induction chemotherapy for acute myeloid leukemia (AML) results in a remission rate of around 70%. Up to 30% of patients do not achieve a remission and approximately 50% of patients who achieve comple...
-
Chapter
Prognostic Models for Primary and Secondary Myelofibrosis
Although patients with primary and secondary myelofibrosis are at risk of disease progression into acute myeloid leukemia, they are heterogenous at presentation and have a highly variable survival. In the last...
-
Chapter
Next-Generation FLT3 Inhibitors for the Treatment of FLT3-Positive AML
Tyrosine kinases regulate a wide range of cellular pathways and are crucial to signal transduction. Their aberrant activities can contribute to leukaemogenesis via promoting proliferation, impeding differentia...
-
Chapter
Management of Relapsed Acute Promyelocytic Leukemia and the Role of Hematopoietic Stem Cell Transplantation
This chapter addresses one of the most controversial issues in the management of acute promyelocytic leukemia (APL) which is the optimal management of relapsed APL following second remission and role of hemato...
-
Chapter
Modern Classification of Acute and Chronic Leukemias: Integrating Biology, Clinicopathologic Features, and Genomics
The modern classification of acute leukemias and myeloid neoplasms has much refinement incorporating clinicopathologic and genomic features with the objective of defining disease entities with information on t...
-
Chapter
Clonal Hematopoiesis and Its Functional Implications in MDS/AML
Clonal hematopoiesis (CH) is now a specifically recognized as a precursor myeloid neoplasm and comprised clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance...
-
Chapter
Allogeneic Hematopoietic Stem Cell Transplantation for MDS and CMML: When and How?
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment in both MDS and CMML. In MDS, there is an increasing prevalence of high-risk MDS undergoing HSCT, whereas only...
-
Chapter
Treatment Algorithm for Primary and Secondary Myelofibrosis
The management of primary myelofibrosis (PMF), postpolycythemia vera myelofibrosis (PPV-MF), and postessential thrombocythemia (PET-MF) is driven by their clinicopathologic and genomic characteristics, and the...
-
Chapter
Eosinophilic Disorders and Systemic Mastocytosis
Eosinophilic disorders are a group of rare and highly heterogenous diseases distinguished by increased eosinophil counts and may be associated with end-organ damage. In this chapter, the diagnostic algorithm a...
-
Chapter
In the Pipeline: Emerging Therapy for CML
The development of BCR-ABL1 tyrosine kinase inhibitors (TKI) has revolutionized the treatment of CML. A major limitation of TKI therapy is the relative inability to eradicate quiescence CML leukemic stem cells...
-
Chapter
In the Pipeline: Emerging Therapy for MDS and MDS/MPN
Novel agents in combination with hypomethylating agents are an emerging strategy for clinical trials in involving higher-risk MDS or MDS/MPN and in patients harbouring high-risk mutations such as those involving
-
Book
-
Chapter
In the Pipeline: Emerging Therapy for Classical Ph-Negative MPNs
Conventional therapy for myeloproliferative neoplasm (MPN) has modest disease-modifying effect. In this chapter, we discuss the emerging novel agents and approaches that may potentially modify the underlying d...
-
Chapter
In the Pipeline: Emerging Therapy for Acute Myeloid Leukaemia
Acute myeloid leukaemia (AML) is an aggressive, heterogenous, and age-related haematological malignancy with dismal prognosis. Conventional therapy for AML consists of frontline induction therapy with cytarabi...
-
Chapter
In the Pipeline—Emerging Therapy for ALL
Despite medical advances in recent decades with improvement in survival rates (Lenk et al., Cancer Metastasis Rev. 2020;39:173–87; Meyer and Hermiston. Cancer Drug Resist. 2019;2: 313–25), decreased treatment ...
